• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

    1.536 +0.077 (+5.24%)
    Streaming Delayed Price Updated: 9:37 AM EST, Dec 30, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 64,520
    Open 1.490
    Bid (Size) 1.520 (2,100)
    Ask (Size) 1.580 (9,200)
    Prev. Close 1.460
    Today's Range 1.480 - 1.550
    52wk Range 1.450 - 8.940
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
    From Medicus Pharma Ltd
    Via GlobeNewswire

    Performance

    YTD
    -38.8%
    -38.8%
    1 Month
    -22.2%
    -22.2%
    3 Month
    -38.8%
    -38.8%
    6 Month
    -48.6%
    -48.6%
    1 Year
    -37.5%
    -37.5%

    More News

    Read More
    News headline image
    Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
    Via ACCESS Newswire
    News headline image
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch
    Via AB Newswire
    News headline image
    Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
    From Medicus Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
    From Medicus Pharma
    Via GlobeNewswire
    News headline image
    Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
    Via ACCESS Newswire
    Medicus Pharma Ltd. (NASDAQ: MDCX) and the Patch That Could End Repetitive Cancer Surgeries
    Via AB Newswire
    Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP)
    Via AB Newswire
    News headline image
    Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
    From Medicus Pharma
    Via GlobeNewswire
    4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)
    Via AB Newswire
    News headline image
    Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
    Via ACCESS Newswire
    4 Diagnostic Stocks Targeting 25%+ Annual Growth in a $20B Market (MDCX, ILMN, EXAS, GH)
    Via AB Newswire
    News headline image
    Three Biotech Companies Redefining Value Creation Through Dual Strategies
    Via ACCESS Newswire
    News headline image
    Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
    Via ACCESS Newswire
    Medicus Pharma (Nasdaq: MDCX) Nears Surgery-Free Breakthrough in Oncology
    Via AB Newswire
    News headline image
    Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
    Via ACCESS Newswire
    Medicus Pharma (Nasdaq: MDCX) Bringing Scar-Free, Outpatient Treatment to an $8 Billion Cancer Market
    Via AB Newswire
    News headline image
    Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
    Via ACCESS Newswire
    News headline image
    Biotech Stocks Positioned to Transform Treatment With Next-Gen Therapeutics
    Via News Direct

    Frequently Asked Questions

    Is Medicus Pharma Ltd. - Common Stock publicly traded?
    Yes, Medicus Pharma Ltd. - Common Stock is publicly traded.
    What exchange does Medicus Pharma Ltd. - Common Stock trade on?
    Medicus Pharma Ltd. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Medicus Pharma Ltd. - Common Stock?
    The ticker symbol for Medicus Pharma Ltd. - Common Stock is MDCX on the Nasdaq Stock Market
    What is the current price of Medicus Pharma Ltd. - Common Stock?
    The current price of Medicus Pharma Ltd. - Common Stock is 1.536
    When was Medicus Pharma Ltd. - Common Stock last traded?
    The last trade of Medicus Pharma Ltd. - Common Stock was at 12/30/25 09:37 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.